<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301934</url>
  </required_header>
  <id_info>
    <org_study_id>18-002297</org_study_id>
    <nct_id>NCT04301934</nct_id>
  </id_info>
  <brief_title>Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection</brief_title>
  <official_title>Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled trial to determine clinical and microbiome difference between&#xD;
      fractional CO2 Laser and vaginal estrogen in treating patients with recurrent urinary tract&#xD;
      infection (UTI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent urinary tract infection (rUTI) is common in postmenopausal women and can lead to&#xD;
      significant bothersome symptoms. This clinical scenario is a difficult and common clinical&#xD;
      problem seen by the urologist and urogynecologist with limited options for treatment. Overuse&#xD;
      of antibiotics has led to significant resistant microorganisms and can have adverse side&#xD;
      effects such as C. Dificile colitis. Current treatments include topical vaginal estrogen and&#xD;
      prophylactic antibiotics. Other supplements such as cranberry pills, methenamine and&#xD;
      D-mannose have varying levels of evidence and efficacy.&#xD;
&#xD;
      Fractional CO2 LASER vaginal therapy has recently been studied for the treatment of GSM.&#xD;
      LASER therapy is currently commercially available and has FDA clearance for use in&#xD;
      gynecology. Current evidence shows that with treatment, histologic changes of the vaginal&#xD;
      epithelium have shown regeneration to a premenopausal state, along with subjective&#xD;
      improvement in GSM symptoms and sexual function. Recent literature has shown improvements in&#xD;
      thickening of vaginal epithelium, decreased vaginal pH and improvement in the vaginal&#xD;
      microbiome. Based on this, the investigators propose fractional CO2 laser may have a positive&#xD;
      impact on women with rUTI.&#xD;
&#xD;
        1. The investigators therefore hypothesize that fractional CO2 LASER vaginal therapy is&#xD;
           non-inferior to topical vaginal estrogen therapy for the treatment of rUTI.&#xD;
&#xD;
           a. Primary Outcome: Improvement in recurrence of culture positive UTI&#xD;
&#xD;
        2. The investigators also hypothesize that LASER therapy will improve the urinary and&#xD;
           vaginal microbiome, decreasing the uropathogenic presence and increasing Lactobacillus.&#xD;
&#xD;
             1. Measurement 1: The number of UTI with UPEC isolated from patients&#xD;
&#xD;
             2. Measurement 2: The pH of the vagina as a proxy for presence of Lactobacillus sp.&#xD;
&#xD;
             3. Measurement 3: Categorize vaginal and urinary microbial communities&#xD;
&#xD;
        3. The investigators hypothesize that LASER therapy will improve symptoms of GSM and be&#xD;
           associated with regenerative change in vaginal histology.&#xD;
&#xD;
             1. Measurement 1: MESA and DIVA surveys of symptoms&#xD;
&#xD;
             2. Measurement 2: Observations of vaginal biopsy between.&#xD;
&#xD;
      Menopausal women will be recruited if subjects have recurrent UTI defined as 3 culture&#xD;
      positive UTIs in 1 year or 2 culture positive UTIs in 6 months. Subjects will be randomized&#xD;
      to standard of care with topical vaginal estrogen or 3 treatments of fractional CO2 LASER of&#xD;
      the vagina. Samples will be collected to show microbiome and histologic changes with&#xD;
      treatment.&#xD;
&#xD;
      Samples include:&#xD;
&#xD;
      Vaginal culture Urine culture vaginal biopsy (optional).&#xD;
&#xD;
      Validated questionnaires and clinical recurrence of UTI will also be gathered over 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in recurrence of culture positive urinary tract infections</measure>
    <time_frame>6 months</time_frame>
    <description>Number of culture positive, symptomatic urinary tract infections in women</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Vaginal Estrogen Therapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mona Lisa Touch</intervention_name>
    <description>Fractional CO2 LASER</description>
    <arm_group_label>Laser Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated estrogen</intervention_name>
    <description>Current standard treatment for recurrent UTIs in postmenopausal women</description>
    <arm_group_label>Vaginal Estrogen Therapy Group</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Current standard treatment for recurrent UTIs in postmenopausal women</description>
    <arm_group_label>Vaginal Estrogen Therapy Group</arm_group_label>
    <other_name>Estrace</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patient &gt;18 years old&#xD;
&#xD;
          -  Postmenopausal status, documented by prior bilateral salpingo-oophorectomy, or absence&#xD;
             of menses &gt;12 months&#xD;
&#xD;
          -  Recurrent urinary tract infections as defined by 3 culture positive urine cultures in&#xD;
             the last 12 months, or 2 positive urine cultures in the last 6 months.(Positive urine&#xD;
             cultures defined by &gt;100K colony forming units of 1 or 2 bacterial species on clean&#xD;
             catch sample, or &gt;1000 colony forming units of 1 or 2 bacterial species on sample via&#xD;
             straight catheterization).&#xD;
&#xD;
          -  Patients on vaginal estrogen must undergo a 1 month washout period prior to initiation&#xD;
             of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematuria without appropriate workup&#xD;
&#xD;
          -  Pelvic organ prolapse at or beyond the hymen&#xD;
&#xD;
          -  Clinically relevant urinary retention&#xD;
&#xD;
          -  Pelvic reconstructive surgery within 6 months&#xD;
&#xD;
          -  Prior synthetic mesh procedure for pelvic organ prolapse or urinary incontinence&#xD;
&#xD;
          -  Clinically relevant nephrolithiasis&#xD;
&#xD;
          -  History of breast cancer&#xD;
&#xD;
          -  Contraindication to topical estrogen therapy&#xD;
&#xD;
          -  Anticoagulation therapy&#xD;
&#xD;
          -  Prior pelvic or vaginal radiation therapy&#xD;
&#xD;
          -  Prior gynecologic malignancy&#xD;
&#xD;
          -  Undiagnosed genital bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Yi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Ryan, CCRP</last_name>
      <phone>480-342-1208</phone>
      <email>ryan.debra29@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Johnny Yi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

